Global Analysis of SARS-CoV-2 Serology, Part 2

Dear Colleagues,

The outbreak of SARS-CoV-2 in late 2019 caused a pandemic, currently in its fourth wave, with a huge medical, societal, and economic impact. Based on detailed knowledge of the viral genome and the major proteins of the virus, molecular and serological assays have been rapidly developed. A wide range of serological assays (both in-house as well as commercial) for SARS-CoV-2 have been validated and implemented. These have been instrumental for diagnostics and for monitoring of the course and severity of COVID-19. For now and in the future, (functional) serological assays will (also) be important for monitoring vaccine coverage against emerging variants of SARS-CoV-2, including the Omicron variant and subvariants. The global aspect and impact of SARS-CoV-2 serology is illustrated through the emergence of variant strains in different parts of the world. In this Special Issue, we aim to bring together views from clinical and basic specialists around the world on the pathogen, its biology, and the vaccines (monovalent and multivalent adapted to omicron variants and others). We welcome your submissions. 

Prof. Dr. Ger Rijkers
Dr. Jean-Luc Murk
Topic Editors